PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Anti-PD-L1 immune checkpoint inhibitor, is approved for the treatment of patients with
unresectable, Stage III NSCLC whose disease has not progressed following concurrent
platinum-based chemotherapy and radiation therapy, or as first-line treatment of patients
with ES-SCLC in combination with etoposide and either carboplatin or cisplatin in China. The
clinical data regarding the PD-L1 inhibitor in other solid tumors are limited.Investigators
would observe and analyze the effectiveness and safety of PD-L1 inhibitor for patients with
advanced - solid tumors beyond lung cancer after muti-line therapy to explore the synergistic
effect of PD-L1 inhibitor rechallenge after PD-1immunotherapy.